Table 2 GLIAS-III flow diagram
Baseline | 96 h (± 6 h) | Day 7 or discharge (± 1 d) | Day 30 (± 2 d) | Day 90 (± 3 d) | |||
|---|---|---|---|---|---|---|---|
Signed informed consent | X | ||||||
Inclusion/exclusion criteria review | X | ||||||
Past medical/surgical history | x | ||||||
Pre-stroke treatments | x | ||||||
Modified rankin scale | (Pre-stroke) | X | X | X | |||
NIHSS | X | X | X | X | X | ||
Reperfusion treatment received | X | ||||||
HbA1c | X | X | |||||
Continuous blood glucose monitoring | < –––––––––––––– > | ||||||
Capillary glucose levels (per local protocols) | < –––––––––––––– > | ||||||
Insulin (type, dosage and route) administered according to local protocols | < –––––––––––––– > | ||||||
Systemic and neurological complications | < ––––––––––––––––––––––––––––––––––––––––– > | ||||||
Stroke etiological subtype | X | ||||||
Secondary stroke prevention treatments | X | X | X | ||||